Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 4
Submit an article Journal homepage
189
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine

Giulia FalconiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Emiliano FabianiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Tiziana OttoneDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; ;Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy; View further author information
,
Alfonso PiciocchiData Center, Fondazione GIMEMA, Rome, Italy; View further author information
,
Serena LavorgnaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Marianna CriscuoloDipartimento Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli, IRCCS, RomaView further author information
,
Luana FianchiDipartimento Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli, IRCCS, RomaView further author information
,
Carmelo GurnariDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Massimiliano PostorinoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Alessandra PicardiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Raffaele PalmieriDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; View further author information
,
Francesco Lo-CocoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; ;Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy; View further author information
&
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; ;Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy; Correspondence[email protected]
View further author information
 show all
Pages 979-982 | Received 18 Sep 2019, Accepted 23 Nov 2019, Published online: 04 Dec 2019

References

  • Mashima K, Ikeda T, Toda Y, et al. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. Leuk Lymphoma. 2019;60(3):703–710.
  • Jiang Y, Liu L, Wang J, et al. The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis. Oncotarget. 2017;9:16205–16212.
  • Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84(9):3071–3079.
  • Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115–2121.
  • Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101(5):1698–1704.
  • Mashima K, Oh I, Ikeda T, et al. Role of sequential monitoring of WT1 gene expression in patients with acute myeloid leukemia for the early detection of leukemia relapse. Clin Lymphoma Myeloma Leuk. 2018;18(12):e521–e527.
  • Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol. 2017;28(7):1547–1553.
  • Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia. 2019;33(3):785–790.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–4649.
  • Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–5201.
  • Luna I, Such E, Cervera J, et al. WT1 isoform expression pattern in acute myeloid leukemia. Leuk Res. 2013;37(12):1744–1749.
  • Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988–1995.
  • Nagasaki J, Aoyama Y, Hino M, et al. Wilms tumor 1 (WT1) mRNA expression level at diagnosis is a significant prognostic marker in elderly patients with myelodysplastic syndrome. Acta Haematol. 2017;137(1):32–39.
  • Morita Y, Maeda Y, Yamaguchi T, et al. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial. Cancer Sci. 2018;109(10):3209–3215.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.